TKI258, a novel, multitargeted tyrosine kinase inhibitor for the treatment of breast cancer

被引：0
|
作者：
Liu, H. [1 ]
Schulz, C. O. [1 ]
Regierer, A. C. [1 ]
Dieing, A. [1 ]
Possinger, K. [1 ]
Eucker, J. [1 ]
机构：
[1] Charite Campus Mitte, Berlin, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14625
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Development of the multi-tyrosine kinase inhibitor TKI258 for patients with metastatic renal cell carcinoma progressing on an mTOR-inhibitor- preliminary results of a phase I/II trial
    Gschwend, J.
    Gruenwald, V.
    Pande, A.
    Albrecht, M.
    Anak, O.
    Escudier, B.
    ONKOLOGIE, 2010, 33 : 105 - 105
  • [22] Dovitinib (TKI258), a Dual Inhibitor of FGFR and VEGFR, Induces Tumor Growth Suppression in Xenograft Models of Primary Human Breast Cancer.
    Shi, M. M.
    Linnartz, R.
    Versace, R.
    Graus, Porta D.
    Kay, A.
    Dugan, M.
    CANCER RESEARCH, 2011, 71
  • [23] Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials
    Kim, Sungkyoung
    Ding, Wenping
    Zhang, Lian
    Tian, Wei
    Chen, Siyu
    ONCOTARGETS AND THERAPY, 2014, 7 : 719 - 728
  • [24] Activating FGFR2 kinase domain mutations provide resistance to dovitinib (TKI258)
    Byron, Sara A.
    Chen, Huaibin
    Mohammadi, Moosa
    Pollock, Pamela M.
    CANCER RESEARCH, 2011, 71
  • [25] In VitroEffect of Dovitinib (TKI258), a Multi-Target Angiokinase Inhibitor on Aggressive Meningioma Cells
    Das, Arabinda
    Martinez Santos, Jaime L.
    Alshareef, Mohammed
    Porto, Guilherme Bastos Ferreira
    Infinger, Libby Kosnik
    Vandergrift, William A., III
    Lindhorst, Scott M.
    Varma, Abhay K.
    Patel, Sunil J.
    Cachia, David
    CANCER INVESTIGATION, 2020, 38 (06) : 349 - 355
  • [26] SunitinibA Multitargeted Receptor Tyrosine Kinase Inhibitor in the Era of Molecular Cancer Therapies
    Georgios S. Papaetis
    Kostas N. Syrigos
    BioDrugs, 2009, 23 : 377 - 389
  • [27] Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib
    Rosenbaum, S. E.
    Wu, S.
    Newman, M. A.
    West, D. P.
    Kuzel, T.
    Lacouture, M. E.
    SUPPORTIVE CARE IN CANCER, 2008, 16 (06) : 557 - 566
  • [28] Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib
    S. E. Rosenbaum
    S. Wu
    M. A. Newman
    D. P. West
    T. Kuzel
    M. E. Lacouture
    Supportive Care in Cancer, 2008, 16 : 557 - 566
  • [29] Sunitinib A Multitargeted Receptor Tyrosine Kinase Inhibitor in the Era of Molecular Cancer Therapies
    Papaetis, Georgios S.
    Syrigos, Kostas N.
    BIODRUGS, 2009, 23 (06) : 377 - 389
  • [30] Oral dysesthesia in cancer patients (Pts) treated with multitargeted tyrosine kinase inhibitors (MT-TKI).
    Yuan, Anna D.
    Kurtz, Sharyn L.
    Barysauskas, Constance
    Pilotte, Amy P.
    Wagner, Andrew J.
    Treister, Nathaniel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345